It’s been a busy year for Natera, the Austin, Texas-based cell-free DNA testing company. On March 10, Natera announced that it was enrolling the first patients in its HEROES Clinical Trial for Metastatic HER2+ Breast Cancer. The Phase II trial explores the discontinuation or de-escalation of anti-HER2 targeted therapy among patients with metastatic HER2+ breast cancer.
The news comes just after a March 4 announcement that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA. Natera has more than 110 patents relating to cell-free DNA analysis for oncology testing, including 23 patents obtained in 2024.
All of this comes on the heels of when, in February, the company announced that its Signatera circulating tumor DNA blood test has met coverage requirements from the Centers for Medicare & Medicaid Services’ Molecular Diagnostics Services Program for patients with non-small cell lung cancer.
